Phase 2 N=36 Improving Therapeutic Learning in Depression: Proof of Concept
Major Depressive Disorder
Primary: Recall of Cognitive Therapy Content — 25.4; 26.8; 24.7; 28.2 Number of correct units of information
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
Leukemia · Myelodysplastic Syndromes
Primary: PHASE I: Maximum Tolerated Dose of Azacitidine — 75 mg/m2 subcutaneously for 5 days
Phase 2 N=130 Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
Leukemia
Primary: Overall Response Rate — 23; 31; 23 Participants
Phase 2 N=48 Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B
Chronic Hepatitis B
Primary: Proportion of Patients With HBsAg Response at 12 Week of Therapy — 0; 0; 1; 0 Participants
Phase 2 N=340 Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults
Influenza
Primary: Number of Participants With Adverse Events — 5; 8; 69; 30 Participants
Phase 2 N=20 Zaleplon in HIV Patients With Depression
HIV/AIDS · Clinical Depression
Primary: Insomnia Severity Index (ISI) — 11 score on a scale
Phase 2 N=49 Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
Breast Cancer · HER2-negative Breast Cancer
Primary: Pathologic Complete Response Rate (ypCR) Following Neoadjuvant Therapy in Breast and Axillary Lymph Nodes — 26.3; 16.7 percentage of participants
Phase 2 N=82 Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia · Stage 0 Chronic Lymphocytic Leukemia · Stage I Chronic Lymphocytic Leukemia
Primary: Arm A: Percentage of Complete Responses — 46 percentage of participants
Phase 2 N=294 Efficacy Study in Patients With Acne Vulgaris.
Acne Vulgaris
Primary: Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts on the Face — -60.84; -62.17 percentage change in lesion counts — p=0.5947
Phase 2 N=50 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
Pheochromocytoma · Paraganglioma
Primary: Number of Patients With Complete (CR), Partial (PR), or Minor (MR) Response and Without Progressive Disease — 28 Participants
Phase 2 N=54 Lactoferrin Treatment in HIV Patients
HIV Infection
Primary: Number of Participants With at Least One Side Effect, Adverse Event, and Serious Adverse Event — 20; 17; 12; 11 Participants
Phase 2 N=270 Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.
Infections, Papillomavirus
Primary: Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 — 163; 1; 150; 2 Participants
Phase 2 N=428 The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
Irritable Bowel Syndrome Characterized by Constipation
Primary: Change From Baseline in Weekly CSBMs Frequency Over the 12-Week Treatment Period (mITT Population) — 1.28; 2.12; 2.74; 2.44 CSBMs per week
Phase 2 N=15 Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI)
Traumatic Brain Injury
Primary: Disability Rating Scale — 12.5; 9.7; 8.5; 6.0 units on a scale — p=0.021
Phase 2 N=240 Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults
Tuberculosis
Primary: Number of Subjects With Grade 3 Solicited Local Symptoms — 1; 0; 1; 0 Participants